Published in J Clin Invest on November 17, 2005
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36
Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol (2008) 2.00
Modeling systems-level regulation of host immune responses. PLoS Comput Biol (2007) 1.56
Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol (2014) 1.40
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol (2010) 1.30
The Bps polysaccharide of Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. Mol Microbiol (2010) 1.25
Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun (2007) 1.15
The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun (2007) 1.09
O antigen protects Bordetella parapertussis from complement. Infect Immun (2008) 1.04
Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect Immun (2008) 1.03
Virulence factor secretion and translocation by Bordetella species. Curr Opin Microbiol (2009) 1.02
Inefficient Toll-like receptor-4 stimulation enables Bordetella parapertussis to avoid host immunity. PLoS One (2009) 1.01
Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity. Infect Immun (2005) 1.00
Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect Immun (2007) 1.00
Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection. Infect Immun (2012) 0.97
Role of the type III secretion system in a hypervirulent lineage of Bordetella bronchiseptica. Infect Immun (2009) 0.97
Differentially expressed genes in Bordetella pertussis strains belonging to a lineage which recently spread globally. PLoS One (2014) 0.95
Characterizing extravascular neutrophil migration in vivo in the iris. Inflammation (2008) 0.93
Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection. Infect Immun (2014) 0.92
Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS One (2011) 0.92
Role of neutrophils in response to Bordetella pertussis infection in mice. Infect Immun (2008) 0.90
O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies. PLoS One (2009) 0.90
IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. J Immunol (2009) 0.89
Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun (2010) 0.89
Lack of cross-protection against Bordetella holmesii after pertussis vaccination. Emerg Infect Dis (2012) 0.88
Lung response to Bordetella pertussis infection in mice identified by gene-expression profiling. Immunogenetics (2007) 0.87
The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. Infect Immun (2009) 0.87
Coughing precipitated by Bordetella pertussis infection. Lung (2010) 0.87
A Type VI secretion system encoding locus is required for Bordetella bronchiseptica immunomodulation and persistence in vivo. PLoS One (2012) 0.85
Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection. PLoS One (2014) 0.82
Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity. Clin Vaccine Immunol (2011) 0.82
A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough. Sci Transl Med (2015) 0.81
Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol (2011) 0.81
sigE facilitates the adaptation of Bordetella bronchiseptica to stress conditions and lethal infection in immunocompromised mice. BMC Microbiol (2012) 0.79
Enhancement of Bordetella parapertussis infection by Bordetella pertussis in mixed infection of the respiratory tract. FEMS Immunol Med Microbiol (2011) 0.79
Contribution of pertussis toxin to the pathogenesis of pertussis disease. Pathog Dis (2015) 0.78
Review of the neutrophil response to Bordetella pertussis infection. Pathog Dis (2015) 0.77
Bacterial Toxins as Pathogen Weapons Against Phagocytes. Front Microbiol (2016) 0.77
Caspase-1-independent interleukin-1β is required for clearance of Bordetella pertussis infections and whole-cell vaccine-mediated immunity. PLoS One (2014) 0.77
Fatal pertussis in the neonatal mouse model is associated with pertussis toxin-mediated pathology beyond the airways. Infect Immun (2017) 0.75
Preliminary studies on the use of pertussis toxin for the modulation of intravaginal SIV transmission in rhesus macaques. J Med Primatol (2017) 0.75
Bacterial toxins: Offensive, defensive, or something else altogether? PLoS Pathog (2017) 0.75
Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet (2003) 9.13
Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol (1986) 4.48
Disease extinction and community size: modeling the persistence of measles. Science (1997) 4.22
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 3.10
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 3.07
Inhibition of receptor-mediated release of arachidonic acid by pertussis toxin. Cell (1984) 2.96
Mutants of pertussis toxin suitable for vaccine development. Science (1989) 2.89
Chaos and biological complexity in measles dynamics. Proc Biol Sci (1993) 2.44
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis (1990) 2.41
Infant pertussis: who was the source? Pediatr Infect Dis J (2004) 2.27
Waves of larch budmoth outbreaks in the European alps. Science (2002) 2.22
The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein. Arch Biochem Biophys (1983) 2.21
Phagocytosis by neutrophils induces an amino acid deprivation response in Saccharomyces cerevisiae and Candida albicans. Proc Natl Acad Sci U S A (2003) 2.19
Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect Immun (1997) 2.15
Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J Bacteriol (1997) 2.14
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo. J Exp Med (2004) 1.89
Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis (2000) 1.85
Pertussis infection in adults with persistent cough. JAMA (1995) 1.84
Pregenomic comparative analysis between bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection. Infect Immun (1999) 1.83
The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr (1984) 1.81
Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med (1997) 1.81
MH-S, a murine alveolar macrophage cell line: morphological, cytochemical, and functional characteristics. J Leukoc Biol (1989) 1.78
Fc receptors. Curr Opin Immunol (1997) 1.74
Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J Biol Chem (1983) 1.74
Role of antibodies in immunity to Bordetella infections. Infect Immun (2003) 1.71
Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis. J Infect Dis (2000) 1.68
Pertussis in German adults. Clin Infect Dis (1995) 1.68
A stochastic model for extinction and recurrence of epidemics: estimation and inference for measles outbreaks. Biostatistics (2002) 1.64
Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J (1998) 1.63
Severe and unrecognised: pertussis in UK infants. Arch Dis Child (2003) 1.62
Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J (1997) 1.62
Prevalence and incidence of adult pertussis in an urban population. JAMA (1996) 1.62
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis (2004) 1.60
Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis (1995) 1.59
Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis (2002) 1.57
Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology (2001) 1.56
Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J Immunol (1985) 1.56
Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med (2000) 1.55
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
The transcriptional responses of respiratory epithelial cells to Bordetella pertussis reveal host defensive and pathogen counter-defensive strategies. Proc Natl Acad Sci U S A (2000) 1.53
The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol (2001) 1.46
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun (1990) 1.44
Household contact study of Bordetella pertussis infections. Clin Infect Dis (1995) 1.35
Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun (2003) 1.26
Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine (2003) 1.21
Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur J Immunol (2004) 1.10
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect Immun (2004) 1.09
The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J Immunol (2005) 1.08
Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect Immun (1984) 1.07
Waning immunity and subclinical measles infections in England. Vaccine (2004) 1.03
Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect Immun (2000) 1.00
Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis (2001) 0.98
Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect Immun (1998) 0.96
Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J Infect Dis (2002) 0.96
Guanine nucleotide activation and inhibition of adenylate cyclase as modified by islet-activating protein, pertussis toxin, in mouse 3T3 fibroblasts. Arch Biochem Biophys (1983) 0.94
Role of pertussis toxin A subunit in neutrophil migration and vascular permeability. Infect Immun (1997) 0.94
A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect Immun (2000) 0.94
Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease. J Infect Dis (2002) 0.93
Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity. J Neuroimmunol (2002) 0.85
Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia. Aust N Z J Public Health (2003) 0.80
Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics (2001) 0.79
Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis (1995) 0.79
Trafficking of neutrophils across airway epithelium is dependent upon both thioredoxin- and pertussis toxin-sensitive signaling mechanisms. J Leukoc Biol (2000) 0.79
A commentary on the pathogenesis of pertussis. Clin Infect Dis (1999) 0.77
PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med (2010) 4.74
Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood (2011) 2.22
Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol (2009) 1.76
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Role of antibodies in immunity to Bordetella infections. Infect Immun (2003) 1.71
Molecular signature of hypersaline adaptation: insights from genome and proteome composition of halophilic prokaryotes. Genome Biol (2008) 1.64
Modeling systems-level regulation of host immune responses. PLoS Comput Biol (2007) 1.56
HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS (2009) 1.46
Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol (2009) 1.45
Rural-urban gradient in seasonal forcing of measles transmission in Niger. Proc Biol Sci (2010) 1.45
HIV latency and integration site placement in five cell-based models. Retrovirology (2013) 1.42
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res (2006) 1.40
Genomic and genetic analysis of Bordetella bacteriophages encoding reverse transcriptase-mediated tropism-switching cassettes. J Bacteriol (2004) 1.36
Bordetella bronchiseptica PagP is a Bvg-regulated lipid A palmitoyl transferase that is required for persistent colonization of the mouse respiratory tract. Mol Microbiol (2003) 1.35
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog (2012) 1.34
Role of Bordetella O antigen in respiratory tract infection. Infect Immun (2003) 1.32
The Bordetella bronchiseptica type III secretion system inhibits gamma interferon production that is required for efficient antibody-mediated bacterial clearance. Infect Immun (2006) 1.31
Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis (2004) 1.31
Comparative genomics of the classical Bordetella subspecies: the evolution and exchange of virulence-associated diversity amongst closely related pathogens. BMC Genomics (2012) 1.30
Evolution and emergence of Bordetella in humans. Trends Microbiol (2005) 1.25
Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect Immun (2005) 1.23
Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem (2004) 1.23
MyD88-dependent signaling contributes to protection following Bacillus anthracis spore challenge of mice: implications for Toll-like receptor signaling. Infect Immun (2005) 1.22
Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine (2010) 1.18
Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology (2007) 1.16
Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One (2013) 1.15
Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology (2008) 1.15
Toll-like receptor 4 is critical to innate host defense in a murine model of bordetellosis. J Infect Dis (2004) 1.14
Comparative phenotypic analysis of the Bordetella parapertussis isolate chosen for genomic sequencing. Infect Immun (2002) 1.13
Toll-like receptor 4-dependent early elicited tumor necrosis factor alpha expression is critical for innate host defense against Bordetella bronchiseptica. Infect Immun (2004) 1.13
Cell-to-cell transmission of viruses. Curr Opin Virol (2012) 1.13
Bordetella type III secretion modulates dendritic cell migration resulting in immunosuppression and bacterial persistence. J Immunol (2005) 1.13
Antibody-mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3. Eur J Immunol (2004) 1.10
The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun (2007) 1.09
The complex mechanism of antibody-mediated clearance of Bordetella from the lungs requires TLR4. J Immunol (2005) 1.08
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci (2008) 1.07
pagP is required for resistance to antibody-mediated complement lysis during Bordetella bronchiseptica respiratory infection. Infect Immun (2004) 1.06
O antigen protects Bordetella parapertussis from complement. Infect Immun (2008) 1.04
Replacement of adenylate cyclase toxin in a lineage of Bordetella bronchiseptica. J Bacteriol (2008) 1.03
Inefficient Toll-like receptor-4 stimulation enables Bordetella parapertussis to avoid host immunity. PLoS One (2009) 1.01
(-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. Obesity (Silver Spring) (2011) 1.01
Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity. Infect Immun (2005) 1.00
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis (2008) 0.99
(-)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice. Food Funct (2011) 0.98
Evolution of acute infections and the invasion-persistence trade-off. Am Nat (2009) 0.98
Role of the type III secretion system in a hypervirulent lineage of Bordetella bronchiseptica. Infect Immun (2009) 0.97
PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci (2007) 0.96
Inhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice. Inflamm Bowel Dis (2016) 0.94
Pertussis pathogenesis--what we know and what we don't know. J Infect Dis (2014) 0.92
Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect (2007) 0.91
Intracellular trafficking of Bordetella pertussis in human macrophages. Infect Immun (2010) 0.91
Delayed role of tumor necrosis factor- alpha in overcoming the effects of pertussis toxin. J Infect Dis (2007) 0.91
Seasonality, cohort-dependence and the development of immunity in a natural host-nematode system. Proc Biol Sci (2008) 0.91
Measles on the edge: coastal heterogeneities and infection dynamics. PLoS One (2008) 0.90
Comparative role of immunoglobulin A in protective immunity against the Bordetellae. Infect Immun (2007) 0.90
O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies. PLoS One (2009) 0.90
Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis. Proc Biol Sci (2010) 0.89
Constraint-based network model of pathogen-immune system interactions. J R Soc Interface (2008) 0.89
Enzymatic modification of lipid A by ArnT protects Bordetella bronchiseptica against cationic peptides and is required for transmission. Infect Immun (2013) 0.89
IL-10 induction by Bordetella parapertussis limits a protective IFN-gamma response. J Immunol (2009) 0.89
Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun (2010) 0.89
Lack of cross-protection against Bordetella holmesii after pertussis vaccination. Emerg Infect Dis (2012) 0.88
The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. Infect Immun (2009) 0.87
Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun (2004) 0.87
Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS One (2009) 0.87
Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2. Mol Cancer Ther (2010) 0.86
A Type VI secretion system encoding locus is required for Bordetella bronchiseptica immunomodulation and persistence in vivo. PLoS One (2012) 0.85
CD11b is required for the resolution of inflammation induced by Bordetella bronchiseptica respiratory infection. Cell Microbiol (2006) 0.85
Evidence for horizontal gene transfer of two antigenically distinct O antigens in Bordetella bronchiseptica. Infect Immun (2009) 0.84
Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression. Carcinogenesis (2010) 0.83
Microarray and functional analysis of growth phase-dependent gene regulation in Bordetella bronchiseptica. Infect Immun (2009) 0.83
Bordetella pertussis acquires resistance to complement-mediated killing in vivo. Infect Immun (2003) 0.82
Evaluation of the stability, bioavailability, and hypersensitivity of the omega-3 derived anti-leukemic prostaglandin: Δ(12)-prostaglandin J3. PLoS One (2013) 0.82
IEIIS Meeting minireview: Bordetella evolution: lipid A and Toll-like receptor 4. J Endotoxin Res (2007) 0.81
Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J Immunol (2011) 0.81
Phenotypic and genomic analysis of hypervirulent human-associated Bordetella bronchiseptica. BMC Microbiol (2012) 0.80
Comparison of the agar block and Lieber-DeCarli diets to study chronic alcohol consumption in an aging model of Fischer 344 female rats. J Pharmacol Toxicol Methods (2012) 0.79
Immunoreactive and bioactive growth hormone responses to resistance exercise in men who are lean or obese. J Appl Physiol (1985) (2011) 0.79
Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen. Infect Immun (2012) 0.79
sigE facilitates the adaptation of Bordetella bronchiseptica to stress conditions and lethal infection in immunocompromised mice. BMC Microbiol (2012) 0.79
Identifying the age cohort responsible for transmission in a natural outbreak of Bordetella bronchiseptica. PLoS Pathog (2010) 0.79
Resident microbiota affect Bordetella pertussis infectious dose and host specificity. J Infect Dis (2013) 0.78
IACUC issues related to animal models of aging. ILAR J (2011) 0.78
Immunization with pneumococcal polysaccharide serotype 3 and lipopolysaccharide modulates lung and liver inflammation during a virulent Streptococcus pneumoniae infection in mice. Clin Vaccine Immunol (2013) 0.77
Horizontally acquired divergent O-antigen contributes to escape from cross-immunity in the classical bordetellae. BMC Evol Biol (2013) 0.77
Identification of a CO2 responsive regulon in Bordetella. PLoS One (2012) 0.77
Use of perphenazine to control cannibalism in DBA/1 mice. Comp Med (2002) 0.76
Antigenic Variation among Bordetella: Bordetella bronchiseptica strain MO149 expresses a novel o chain that is poorly immunogenic. J Biol Chem (2010) 0.76
Ectopic Expression of Innate Immune Protein, Lipocalin-2, in Lactococcus lactis Protects Against Gut and Environmental Stressors. Inflamm Bowel Dis (2017) 0.75
Vitamin A toxicity and vitamin E deficiency in a rabbit colony. Contemp Top Lab Anim Sci (2004) 0.75